Concerns are emerging about the protection of persons taking part in genetic research involving biobanks. We used several items of a questionnaire sent to the 48 French research ethics committees (RECs) to investigate the means by which they evaluate the constitution and use of biobanks and the elements on which conclusions were based.
INTRODUCTION
The collection of human biological material and phenotypic data is essential for genetic research. The French Code of Public Health (CPH) defines a collection, in the context of genetic research, as a cluster of "biological samples for use in genetic research, obtained from a group of identified patients selected according to the clinical or biological characteristics of one of more members of a group, as well as any and all derivatives of these samples" (art L.1131-4). It may consist of solid tissues, blood, saliva, or any other tissue or fluid containing nucleated cells. The biological material is associated with files (often computer files) that may contain identified, identifiable, directly anonymous data or data rendered anonymous (anonymized). We will use the term "biobank" to cover all activities relating to the storage of human biological materials.
In theory, RECs must approve all biomedical research studies, including those involving the collection of human materials, which may cause harm to the individual in his psychological and social dimensions. This view was laid down in the 1975 Declaration of Helsinki. In France, the "Huriet Law" of December 20, 1988 [1] , now part of the CPH, sets out the legal requirements concerning the protection of individuals involved in biomedical research. It has led to the constitution of RECs, also known as CCPPRBs Ethical and legal issues raised by the constitution of biological collections include organizational and medical aspects of storage duration and sample reuse. Some studies have explored practices concerning the constitution and use of collections [2] [3] [4] . In pharmacogenetic studies, clarification of the procedures concerning confidentiality, information sharing and guarantees concerning DNA storage and usage are required [5] .
In 1994 [6] , it was suggested that "...the constitution of the collection…requires the opinion of the REC" and, in 1998 [7] , that "…an agreement will take into account measures involved in the collection, storage and abusive use (such as use in the context of employment, insurance …) of samples and any information concerning them".
In this study, we investigated the views of French RECs concerning their current and ideal involvement in the constitution and use of biobanks and concerning the ethical rules necessary to protect people involved in this kind of activity. According to the former NBAC (National Bioethics Advisory Commission of the USA), it is essential that IRBs (Institutional Review Boards) evaluate research involving human biological resources [8] . The integration of biobank evaluation into the work of RECs has been proposed as part of a project to revise French law concerning biomedical research, with a view to applying a European directive [9] [10] .
METHODS
The RECs appear to be appropriate bodies for evaluating research projects involving biobanks. They are concerned about the necessity to inform participants, to obtain consent for sample use, confidentiality, and decisions concerning the transmission of research findings to the participants. These points are coherent elements in the 8 recognized role and daily practice of RECs. However, questions concerning the fate of the bank and conditions of access and exchange appear to be taken into account to a lesser extent.
The RECs also have a role to play in determining whether overall and/or individual results should be transmitted to participants. They may be involved in the decision to use directly anonymous data (no link between the data and the participant) or to render identifiable data anonymous (thereby destroying the link between the sample and the individual). The use of anonymous data precludes the communication of individual results and this element must be considered when consent is sought.
Standardized consent forms for use in genetics have been proposed [11] [12] . Clauses have been drafted for numerous issues: sample storage, benefits, risks, confidentiality, communication of results to the patients, genetic counseling, possibilities of transfer or commercialization, and time for reflection before giving consent. International harmonization of ethical controls on genetic research projects would be desirable, rendering consistent the rules applied to the content of information, the consent form, and the functioning of biobanks. This is becoming increasingly important with the growing number of international projects and differences in the constitution, use, reuse and transfer of biological samples. Indeed, these activities are not necessarily routinely evaluated by RECs as they are not covered by laws concerning biomedical research.
